GENE ONLINE|News &
Opinion
Blog

Merck
R&D Combination Therapy
Xilio Collaborates With Merck to Evaluate Combo of CTLA-4 and PD-1 Blockers Against Solid Tumors
2021-05-26
COVID-19 Remdesivir
As India Suffers Crisis, Merck Signs License Pact with 5 Indian Firms to Manufacture COVID-19 Drugs
2021-04-29
M&A Healthcare
Merck Spinoff Expands Healthcare Business by Investing $240 Million in Acquiring Alydia Health
2021-03-31
Trials & Approvals Anti-PD-1
Merck’s Anti-PD1 Therapy Receives Second FDA Approval for Esophageal Carcinoma
2021-03-25
R&D HIV
Gilead, Merck Unite to Contest ViiV’s Cabenuva with Long-Acting HIV Therapy
2021-03-16
COVID-19 Anti-COVID Drug
Merck Says Preliminary Trial Findings of Oral COVID-19 Drug Encouraging
2021-03-08
M&A Autoimmune Disease
Merck Acts on its Post-Keytruda Plan, Spends $1.85B to Acquire Pandion for Autoimmune Therapies
2021-02-26
COVID-19 Vaccine
Merck Withdraws from COVID-19 Vaccine Race Due to Sub-par Response
2021-01-25
R&D Heart Failure
Merck and Bayer Enter the Congested Market of Heart Failure with Verquvo
2021-01-21
Key Takeaways from the JPM Healthcare Conference: Gilead, Regeneron Lay Oncology Plans, Merck Looks Beyond Keytruda
2021-01-17
Trials & Approvals PARP Inhibitor
Lynparza Bags Multiple Approvals in Japan
2021-01-05
Trials & Approvals
ASH2020: VelosBio’s ROR1 Targeted Therapy Shines in Safety Trial
2020-12-09
COVID-19 Recombinant Fusion Protein
Merck Spends $425 Million to Acquire OncoImmune’s COVID-19 Therapy
2020-11-24
Trials & Approvals Renal Cell Carcinoma
Merck, Eisai’s Combo Therapy Registers Superiority against Pfizer’s Drug in Kidney Cancer Trial
2020-11-15
M&A B-cell Lymphoma
Hot Pursuit for Antibody Drug Conjugates Continue as Merck Acquires VelosBio
2020-11-06
1 2 3 4 5 6 7
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top